Autolus Therapeutics (AUTL) Announces Publication Describing its Controllable CAR T Cell System
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
AUTL (AUTL) PT Raised to $6.50 at Goldman Sachs
November 9, 2021 4:34 AM ESTGoldman Sachs analyst Graig Suvannavejh raised the price target on AUTL (NASDAQ: AUTL) to $6.50 (from $5.50) while maintaining a Neutral rating.... More
Autolus Therapeutics (AUTL) Deal with Blackstone Overall Positive - Mizuho
November 8, 2021 1:03 PM ESTMizuho Securities analyst Mara Goldstein reiterated a Buy rating and $18.00 price target on Autolus Therapeutics (NASDAQ: AUTL) after catching up with management following today's Blackstone deal.
Goldstein notes the funding model is minimally dilutive to obe-cel's earning potential and the access to capital... More
Pre-Open Stock Movers 11/08: (AUTL) (TTD) (BLNK) Higher; (EHTH) (BLUE) (TSLA) Lower (more...)
November 8, 2021 8:50 AM ESTPre-Open Stock Movers:
Autolus Therapeutics plc (Nasdaq: AUTL) 27.2% HIGHER; announced that the two companies have entered into a strategic collaboration and financing agreement under which funds managed by Blackstone (NYSE: BX) will provide up to $250 million in equity and product financing to support Autolus advancement of its CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as next generation product therapies of obe-cel in B-cell malignancies.
Autolus Therapeutics (AUTL) Announces $250M Investment from Blackstone (BX) to Advance CAR T Development
November 8, 2021 5:41 AM ESTAutolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Blackstone Life Sciences today announced that the two companies have entered into a strategic collaboration and financing agreement under which funds managed by Blackstone (NYSE: BX) will provide up to $250 million in equity and product financing to support Autolus advancement of its CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as next generation product therapies of obe-cel in B-cell malignancies.
As part of this $250 million transaction,... More
